Whalesbook
📉 The Financial Deep Dive
The Numbers:
Aurobindo Pharma announced its Q3FY26 results, posting consolidated revenue from operations of ₹8,646 Crores, an increase of 8.4% year-on-year (YoY) from ₹7,979 Crores in Q3FY25. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 9.0% YoY to ₹1,773 Crores, with an improved EBITDA margin of 20.5% (up 11 bps YoY). Net Profit attributable to owners stood at ₹910 Crores, a 7.6% increase from ₹846 Crores in the prior year period. Reported Earnings Per Share (EPS) was ₹15.67, up 7.7% YoY. An exceptional item of ₹-65 Crores was recorded during the quarter.
The Quality:
Gross Profit increased by 10.8% YoY to ₹5,165 Cr, with Gross Margin improving to 59.7%. Free Cash Flow generated during the quarter was US$ 118 million, indicating healthy cash generation relative to net profit.
Management Commentary and Future Strategy:
While specific quantitative forward-looking guidance figures were not explicitly stated, the company emphasized its strategic focus on developing its biosimilars pipeline through CuraTeQ Biologics. This division is positioned to target a significant addressable market opportunity estimated at over $50 billion by 2032. Key biosimilar candidates such as Denosumab (BP16) and Omalizumab (BP11) are progressing, with planned European Marketing Authorisation Application (MAA) and US Biologics License Application (BLA) submissions. Pre-submission meetings with the US Food and Drug Administration (FDA) for a bevacizumab biosimilar have commenced, targeting a Q2/Q3 CY2026 filing.
Income Statement Drivers:
Revenue growth was significantly propelled by a 27.4% YoY increase in Europe and a 22.4% YoY rise in the Antiretroviral (ARV) segment. The US market demonstrated stable performance with 2.2% YoY growth, despite lower transient product sales. The Active Pharmaceutical Ingredient (API) business experienced a 4.3% YoY decline, attributed to challenging market conditions. Other Income saw a notable 33.3% QoQ increase.
Balance Sheet:
The company maintained a strong net cash position, standing at approximately US$ 251 million (including investments) as of December 2025, after accounting for the Khandelwal Labs acquisition.
Risks & Outlook:
The API business's performance declined 4.3% YoY, reflecting market challenges. The company anticipates continued growth from its European operations and the ARV segment. The development and eventual launch of biosimilars represent a significant long-term opportunity for sustained expansion. Key risks include potential volatility in the API market and broader macroeconomic factors. The filing timeline for the Denosumab biosimilar (BP16) has been delayed due to extended validation requirements and ongoing clinical study commitments.